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tects against the loss of barrier function. The LPS-induced actin 
reorganization is also tyrosine phosphorylation-dependent. 
Conclusions: LPS directly influences endothelial barrier fUnc- 
tion through tyrosine phosphorylation-dependent actin reorganiza- 
tion and opening of the paracellular pathway. 
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1 S188 I Microbial-Leukocyte-Endothelial Cell 
Interactions and Altered Penneabili of the 
Blood-Brain Barrier during Meningitis 
G.C. Townsend, WM. Scheld. University of Krg'nia School o j  
Medicine, Charfoffesville, VA, USA 
Bacterd meningitis (BM) is characterized by the presence of poly- 
morphonuclear neutrophils (PMNs) within the subarachnoid space. 
Evidence indicates that hgh cerebrospmal fluid concentrations of 
PMNS contribute significantly to the poor outcomes resulting from 
BM. Much of the research being conducted BM has focused on the 
identification of host factors that may contribute to this process. 
Interactions between bacteria, PMNs, and the cerebral microvas- 
cular endothelial cells (CMVECs) that comprise the blood-brain 
barrier likely play a sigmficant role in the generation of the host 
inflammatory response and in the development of the pathophysio- 
logic events that occur during BM. Exposure of CMVECs to certain 
bacterial components or to endogenous proinflammatory mediators 
stimulates production and release of factors that are chemotactic for 
and/or activate PMNs. Increased expression and avidity of leuko- 
cyte-endothelid cell adhesion molecules on PMNs and on CMVECs 
fadtate localization and transendothelial migration of PMNS. Bac- 
teria, PMNs, and their products may also have deleterious effects on 
CMVECs, thus compromising the integrity of the blood-brain bar- 
rier and the ability of the CMVECs to maintain homeostasis within 
the central nervous system. Advances in the understanding of these 
interactions may help to idenhfy targets to direct agents that may be 
used in the adjunctive therapy of BM. 
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Influenza and pneumococcal vaccination for 
older adults in Western Europe 
[ s190 I The Epidemiology of Influenza and 
Pneumococcal Infections 
J. Henrichsen. Sfatens Serum Insfifuf, Copenhagen, Denmark 
Due to antigenic drifl influenza A and B viruses usually cause 
epidemics of influenza in Europe and elsewhere 5-6 times over 
a 10-year period. Antigenic shift in influenza A virus may cause 
changes that make most of the worlds population susceptible leading 
to influenza pandemics. This happened in 1900, 1918 ("The Span- 
ish flu"), 1957 (Asiatic flu), 1968 (Hong Kong flu) and possibly in 
1995. In Denmark with a population of little over 5 mio, influenza 
epidemics led to an excess mortality of 1400 in 1989190, of 2000 in 
1993/94 and of 2800 in 1995/96. So, obviously, there is much to be 
obtained by prevention. 
Over the last twenty years the number of cases of invasive pneu- 
mococcal disease has increased ten times in Denmark - as well as 
reportedly in Norway The incidence was 20 cases per 100,000 in- 
habitants in 1995 and the highest rates were seen in the very young 
(23/100,000) and in the elderly (55/100,000). The ten first types 
in order of kquency represented 65% of all isolates f b m  patients 
of all ages and as many as 85% of isolates from children with some 
variation as to whch types actually were the ten most common over 
the years. 
Types present in the currently available 23-dent pneumococcal 
polysaccharide vaccines over the last 20 years have covered ca. 90% 
of all invasive dlsease isolates in most countries and in all age groups. 
ml The Clinical Effectiveness, Cost-Effectiveness 
and Implementation of Influenza Vaccination 
R. Snacken. Insfifufefor Hygiene and Epidemiolon, Brussels, Belgium 
Several s t u d m  have shown that influenza vaccines prevent 60 to 90% 
of natural-occurring influenza virus infections in adults. Among the 
elderly, influenza vaccination prevents 30 to 60% of duenza-related 
hospitalizations, and 30 to 54% of all-causes mortality. Additional 
studies have shown that the cost-effectiveness of influenza vacci- 
nation exceeds that of h o s t  all other preventive, screening and 
treatment measures used in the care of older persons. In the Nether- 
lands, a recent cost-effectiveness study led public health authorities 
to m o w  their policy and to include age 265 years as an indication 
for influenza vaccination. Currently, only four Western European 
countries have influenza vaccination policies that target only at-risk 
persons. Not surprisingly, great ddferences s t i l l  exist among these 
countries in their use of influenza vaccine, in 1995 the number of 
doses distributed ranged fium 48 to 170 doses per 1000 total pop- 
ulation. The reasons underlymg the persistent variations in vaccine 
use remain poorly understood. With this in mind, the European 
Scientific Working group on Influenza (ESWI) has initiated sev- 
eral socioeconomic studies of influenza and undertaken surveys on 
surveillance and diagnostic methods, immunization rates, and ed- 
ucational programs for health care providers and the public. The 
goal of these studies is to improve the implementation of influenza 
immunization policies throughout Europe. 
I 3 9 2  I The Clinical Effectiveness, Cost Effectiveness 
and Implementation of Pneumococcal 
Vaccination 
A. Hall. London School of Hygiene G. Tropical Media'ne, UK 
Pneumococcal infections are a major cause of morbidity and mor- 
tatity in adults resulting in increased costs to the health care sector 
as well as to the individual. Clinical trials and observational s t u d m  
(both case control and retrospective cohort designs) have examined 
the e5cacy and dectiveness of vaccination in older individuals. 
Clinical trials have failed to show efficacy against pneumococcal 
pneumonia largely because of methodological problems or unrep- 
resentative sample populations. The observational studies however 
have shown a c h i d  effectiveness of 50 to 70% in preventing in- 
wive pneumococcal disease. Cost effechveness studies conducted in 
the United States and more recently in The Netherlands and Spain 
sugest suggest vaccination of older people (over 64 years) to prevent 
pneumococcal pneumonia would be worthwhile, and a recent study 
from the US has shown that vaccination to prevent pneumococcal 
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bacteraemia alone would be cost-saving. This latter study and recent 
evidence that the incidence of invasive pneumococcal msease is sim- 
llar in western Europe and the US support the use of pneumococcal 
vaccine as a public health measure. However, use has been limited 
in western Europe until the last few years. Since 1994 pneumococ- 
cal vaccine uptake has increased dramatically in Iceland, the UK, 
Sweden, Belgium and Norway. In other countries there has been 
little or no change. DBerences between countries in vaccine recom- 
mendations and reimbursement probably account for some of these 
KUiatiOnS. 
I S 193 I Prospects for New and Improved Influenza and 
Pneumococcal Vaccines 
D.S. Fedson. Pasteur Mhieux M S D ,  Lyon, France 
Interest in new and improved influenza and pneumococcal vaccines 
is widespread, but many difficulties must be overcome before they 
massive migration of populations in search of work or food; and 
collapse of already stmined public health h t r u c t u r e .  
Collapse of the public health h t r u c t u r e  is clearly demonstrated 
by the ongoing epidemic of dengue in Latin America, the result 
of a breakdown in mosquito control; and the amplification of the 
recent Ebola epidemic in Zaire, facilitated by sub-standard hospital 
mfection control practices. Recent importations of yellow fever into 
Switzerland and the United States attest to the intensity of inter- 
national travel for pleasure, while deforestation and irrigation may 
provide the opportunities for vectors of viral pathogens to reproduce 
in ever greater numbers. 
In the world of today viral pathogens will continue to emerge and 
reemerge, but reinforced surveillance, laboratories and public health 
dastructure will ensure their early detection and control. 
m] Old and Newly Discovered European Hantavirus 
Infections 
are introduced. Live attenuated influenza vaccines are immunogenic 
and well tolerated and &cal trials are underway in chddren. How- 
ever, they may be useful in older adults only to supplement current 
inactivated vaccines. Several adjuvanted d u e n z a  vaccines are be- 
ing tested &cally, but in many instances their increased immuno- 
genicity has been oftset by increased side effects. Influenza DNA 
vaccines are of greatest interest. Experimental studies show that im- 
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munization with the DNA of internal protein (NF') and surface (H) 
antigens elicits protection against heterotypic dection (presumably 
NP-mediated) as well as antibodies to the homotypic H antigens, 
and Phase I c h i d  trials have recently begun. For pneumococ- 
cal vaccines, studies in chddren have shown that conjugate vaccines 
(PCV) are immunogenic, prime for booster responses to polysac- 
charide (PV) vaccine and reduce naso-pharyngeal carriage. Similar 
immunogenicicy and priming have been demonstrated in adults. EU- 
perimental protein-based (e.g., PspA, pneumolysin) vaccines promise 
to be cross-protective against many different capsular type pneumo- 
coccal infections, but have not been directly compared to PV or 
PCV. The future clinical utility of new or improved influenza and 
pneumococcal vaccines appears promising for children, whereas the 
advantages they will offer over current vaccines in the elderly may 
be marginal. Their greatest promise may lie in the immunization of 
older children and non-elderly adults, persons hitherto not consid- 
ered candidates for either vaccine. 
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I S194 1 Emerging Viral Pathogens 
D.L. Heymann. The World Health Organization Division o f E m q ' n g  
and Other Communicable Diseases Surveillance and Control (EMC), 
Avenue Appia, Geneva, Switzerland 
Emerging viral pathogens such as sin nombre or Ebola provide ev- 
idence of the ability of viral pathogens to cross the species barrier 
to man, while others such as hepatitis C and HIV highlight their 
insidious nature. Several factors contribute to the emergence and or 
recognition'of new viruses. Most can be linked directly or indirectly 
to the increasing numbers of people living on the earth. The re- 
sult is intenslfication in international travel for business or pleasure; 
increased exposure to disease vectors and reservoirs in areas once 
d b i t e d ;  changes in ecology with deforestation and irrigation; 
In Europe hantaviruses infecting humans include Puumala virus 
causing mild hemorrhagx fever with renal syndrome 
(HFRS) also known as nephmpathia epidemica (NE), Dobrava and 
probably Hantaan (causing severe HFRS) and Seoul viruses (caus- 
ing HFRS). These infections may be conveniently diagnosed using 
IgG, I@ and IgG-avidity enzyme immunoassays based on the use 
of capture antibodies and recombinant baculovirus-expressed PUU 
and HTN nucleocapsid proteins. In addition, using immunological 
screening of rodents followed by PCR, genetic analysis and subse- 
quent virus isolation, we have discovered Tula virus (TUL.) h m  Eu- 
ropean common voles and Topografov virus (TOP) &om lemmings. 
We have shown that TUL can d e c t  humans but the pathogenicity 
of TUL and TOP are not yet known. Phylogenetic analyses show 
that (i) hantaviruses are coevolving with their ~ t u r a l  carrier rodents, 
(ii) genetic variants are clustered according to their geographic origin 
and (iii) hantaviruses in individual hosts are represented as complex 
mixtures of closely related genetic and antigenic variants (quasis- 
pecies). Our results show that the severity of NE is associated with 
HLA B8 DR3 haplotype and correlates with the relative ease of 
RT-PCR detection of PUU sequences h m  patient blood and urine. 
In contrast, HLA B27 is associated with a mild course of NE. 
I S196 I Community respiratory virus infections in 
immunocompromised patients. When the trivial 
becomes fatal 
E. Whunbey. The Univenity of Z x a  M .  D. Anderson Cancer Center, 
Houston, TX, USA 
Community respiratory viruses (CRV) have emerged as a major 
cause of life-threatening pneumonia in immunocompromised pa- 
tients. Recent studies have revealed that a minimum of 20%-30% 
of patients with leukemia and BMT recipients hospitalized with an 
acute respiratory illness are infected with a CRV (respiratory syn- 
o/tlal virus, influenza viruses, parainfluenza viruses, adeno-viruses, 
picornaviruses). Approximately 60% of these infections are com- 
plicated by pneumonia, with an associated mortality of 50%. The 
illnesses range from seemingly trivial upper respiratory illnesses to 
fatal pneumonias (and occasionally other organ disease) depending 
largely on the type of virus, and the type, degree and duration of 
